Gabapentin Capsule
Product Images NDC 72789-055

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72789-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789055 (72789055)

Gabapentin USP 300 mg capsules label from PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label shows a package containing 180 capsules with NDC 72789-055-93. It includes warnings about drowsiness, avoiding alcohol, and not taking antacids simultaneously. The label also contains reorder number 111087, lot number F20C11, and expiration date 06/2022, with instructions to see the package insert for dosage and storage.*

FDA Label Image

1 (Image 1)

A mathematical formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and sex, incorporating an adjustment factor of 0.85 for female patients. This text panel provides guidance on pharmacokinetic adjustments relevant to drug dosing considerations.*

FDA Label Image

Image 10

Gabapentin 300 mg oral capsules. The image shows a single capsule that is orange and yellow in color. The labeler is PD-Rx Pharmaceuticals, Inc. The product NDC is 72789-055.*

FDA Label Image

Image 2

Gabapentin 300 mg oral capsule, as shown on the capsule image from PD-Rx Pharmaceuticals, Inc. The capsule is blue and white, imprinted with '72789-055' on the blue half. It is a prescription drug dosage form for oral administration.*

FDA Label Image

1 (Image 5)

Chemical structure diagram showing the molecular structure of gabapentin with a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

1 (Image 6)

A line graph depicting mean pain scores over an 8-week period, comparing a placebo group with a Gabapentin group receiving 3600 mg/day. The x-axis shows weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain scores for the Gabapentin group compared to placebo.*

FDA Label Image

2 (Image 7)

A line graph showing mean pain score over seven weeks comparing three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period; the y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show decreasing pain scores over time compared to placebo.*

FDA Label Image

3 (Image 8)

A bar chart comparing percent values for placebo (PBO) versus Gabapentin (GBP) at different dosages across two studies. Study 1 shows PBO at 12% and GBP 3600 mg at 29%, while Study 2 shows PBO at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance levels (p < 0.01 and p < 0.001) are indicated above GBP bars.*

FDA Label Image

4 (Image 9)

A scatter plot showing differences (%) on the y-axis versus daily dose (mg) on the x-axis for Gabapentin 300 mg capsules. Data points are grouped by three studies labeled a, b, and c, with daily doses ranging from 600 mg to 1800 mg and differences between approximately 7% and 18%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.